A genotypic resistance assay for the detection of drug resistance in the human immunodeficiency virus type 1 envelope gene

被引:39
作者
Van Laethem, K
Schrooten, Y
Lemey, P
Van Wijngaerden, E
De Wit, S
Van Ranst, M
Vandamme, AM
机构
[1] Rega Inst, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven Hosp, Microbiol & Immunol Clin & Epidemiol Virol AIDS R, B-3000 Louvain, Belgium
[3] Ctr Hosp Univ St Pierre, Med Ctr St Peter, Brussels, Belgium
关键词
RNA extraction; cDNA synthesis; PCR; HIV-1; subtypes; sensitivity;
D O I
10.1016/j.jviromet.2004.09.003
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Since it is not clear yet whether enfuvirtide resistance is restricted to gp41, it was decided to develop a genotypic assay for the detection of drug resistance in the entire human immunodeficiency virus type 1(HIV-1) env gene. Given the increasing prevalence of HIV-1 non-B subtypes in Europe, it is important to evaluate the performance of the assay on a panel of genetically divergent samples. A panel of I laboratory and 10 clinical isolates from 10 patients was tested, all enfuvirtide naive and chosen according to the subtype as determined in the pol region (A, B, C, H, CRF01-AE, CRF02-AG, CRF05-DF, CRF11-cpx and U), while their env sequences belonged to subtypes A, 13, C, H, A/G recombinant, B/H recombinant, CRF01-AE, CRF02-AG, CRF05-DF and CRF11-cpx. The detection limits of the gp120 and the gp41 PCRs ranged between 500 and 5000 RNA copies/ml plasma. The highest sensitivity was obtained for the laboratory strain, whereas the detection limit for all patient samples, except for the subtype C sample, was 1000 RNA copies/ml. The numerous insertions and deletions in the gp120 gene, that were often present as quasi-species, necessitated the sequencing of cloned PCR products. The gp41 gene displayed less diversity and less insertions/deletions. Especially, the heptad repeat 1 was highly conserved and none of the enfuvirtide naive samples contained any of the already known enfuvirtide resistance mutations at amino acid positions 36-45. This study demonstrates that the assay is able to genotype genetically diverse HIV-1 strains with a good sensitivity. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:25 / 34
页数:10
相关论文
共 19 条
[1]   Core structure of gp41 from the HIV envelope glycoprotein [J].
Chan, DC ;
Fass, D ;
Berger, JM ;
Kim, PS .
CELL, 1997, 89 (02) :263-273
[2]   Sensitivity of human immunodeficiency virus type 1 to fusion inhibitors targeted to the gp41 first heptad repeat involves distinct regions of gp41 and is consistently modulated by gp120 interactions with the coreceptor [J].
Derdeyn, CA ;
Decker, JM ;
Sfakianos, JN ;
Zhang, ZJ ;
O'Brien, WA ;
Ratner, L ;
Shaw, GM ;
Hunter, E .
JOURNAL OF VIROLOGY, 2001, 75 (18) :8605-8614
[3]   Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120 [J].
Derdeyn, CA ;
Decker, JM ;
Sfakianos, JN ;
Wu, XY ;
O'Brien, WA ;
Ratner, L ;
Kappes, JC ;
Shaw, GM ;
Hunter, E .
JOURNAL OF VIROLOGY, 2000, 74 (18) :8358-8367
[4]   N- and C-domains of HIV-1 gp41: mutation, structure and functions [J].
Dong, XN ;
Xiao, Y ;
Dierich, MP ;
Chen, YH .
IMMUNOLOGY LETTERS, 2001, 75 (03) :215-220
[5]  
Greenberg ML, 2002, ANTIVIR THER, V7, pS14
[6]   Resistance mutation in HIV entry inhibitors [J].
Hanna, SL ;
Yang, CF ;
Owen, SM ;
Lal, RB .
AIDS, 2002, 16 (12) :1603-1608
[7]   Membrane-anchored peptide inhibits human immunodeficiency virus entry [J].
Hildinger, M ;
Dittmar, MT ;
Schult-Dietrich, P ;
Fehse, B ;
Schnierle, BS ;
Thaler, S ;
Stiegler, G ;
Welker, R ;
von Laer, D .
JOURNAL OF VIROLOGY, 2001, 75 (06) :3038-3042
[8]   Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry [J].
Kilby, JM ;
Hopkins, S ;
Venetta, TM ;
DiMassimo, B ;
Cloud, GA ;
Lee, JY ;
Alldredge, L ;
Hunter, E ;
Lambert, D ;
Bolognesi, D ;
Mathews, T ;
Johnson, MR ;
Nowak, MA ;
Shaw, GM ;
Saag, MS .
NATURE MEDICINE, 1998, 4 (11) :1302-1307
[9]  
KUIKEN C, 2002, THEORETICAL BIOL BIO, P611
[10]   Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors [J].
Labrosse, B ;
Labernardière, JL ;
Dam, E ;
Trouplin, V ;
Skrabal, K ;
Clavel, F ;
Mammano, F .
JOURNAL OF VIROLOGY, 2003, 77 (02) :1610-1613